Logo image of BLUE

BLUEBIRD BIO INC (BLUE) Stock Fundamental Analysis

NASDAQ:BLUE - Nasdaq - US09609G1004 - Common Stock - Currency: USD

4.08  -2.96 (-42.05%)

After market: 3.99 -0.09 (-2.21%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BLUE. BLUE was compared to 571 industry peers in the Biotechnology industry. BLUE may be in some trouble as it scores bad on both profitability and health. BLUE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BLUE has reported negative net income.
BLUE had a negative operating cash flow in the past year.
BLUE had negative earnings in each of the past 5 years.
In the past 5 years BLUE always reported negative operating cash flow.
BLUE Yearly Net Income VS EBIT VS OCF VS FCFBLUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200M -400M -600M -800M

1.2 Ratios

The Return On Assets of BLUE (-64.62%) is worse than 62.17% of its industry peers.
Industry RankSector Rank
ROA -64.62%
ROE N/A
ROIC N/A
ROA(3y)-73.42%
ROA(5y)-60.14%
ROE(3y)-154.55%
ROE(5y)-114.15%
ROIC(3y)N/A
ROIC(5y)N/A
BLUE Yearly ROA, ROE, ROICBLUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

BLUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLUE Yearly Profit, Operating, Gross MarginsBLUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K -20K

More info and screens

1

2. Health

2.1 Basic Checks

BLUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BLUE has less shares outstanding
Compared to 5 years ago, BLUE has less shares outstanding
BLUE has a worse debt/assets ratio than last year.
BLUE Yearly Shares OutstandingBLUE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
BLUE Yearly Total Debt VS Total AssetsBLUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

BLUE has an Altman-Z score of -15.86. This is a bad value and indicates that BLUE is not financially healthy and even has some risk of bankruptcy.
BLUE has a worse Altman-Z score (-15.86) than 83.66% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.86
ROIC/WACCN/A
WACC8.52%
BLUE Yearly LT Debt VS Equity VS FCFBLUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 0.51 indicates that BLUE may have some problems paying its short term obligations.
The Current ratio of BLUE (0.51) is worse than 93.25% of its industry peers.
A Quick Ratio of 0.33 indicates that BLUE may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.33, BLUE is doing worse than 94.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.51
Quick Ratio 0.33
BLUE Yearly Current Assets VS Current LiabilitesBLUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for BLUE have decreased strongly by -2960.86% in the last year.
The Revenue has grown by 143.67% in the past year. This is a very strong growth!
Measured over the past years, BLUE shows a very negative growth in Revenue. The Revenue has been decreasing by -11.58% on average per year.
EPS 1Y (TTM)-2960.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-839.39%
Revenue 1Y (TTM)143.67%
Revenue growth 3YN/A
Revenue growth 5Y-11.58%
Sales Q2Q%-14.36%

3.2 Future

BLUE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.61% yearly.
BLUE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 64.23% yearly.
EPS Next Y35.36%
EPS Next 2Y32.12%
EPS Next 3Y18.57%
EPS Next 5Y14.61%
Revenue Next Year74.73%
Revenue Next 2Y143.81%
Revenue Next 3Y95.72%
Revenue Next 5Y64.23%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BLUE Yearly Revenue VS EstimatesBLUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
BLUE Yearly EPS VS EstimatesBLUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLUE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLUE Price Earnings VS Forward Price EarningsBLUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLUE Per share dataBLUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as BLUE's earnings are expected to grow with 18.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.12%
EPS Next 3Y18.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BLUE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUEBIRD BIO INC

NASDAQ:BLUE (2/21/2025, 8:03:47 PM)

After market: 3.99 -0.09 (-2.21%)

4.08

-2.96 (-42.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-24 2025-03-24/amc
Inst Owners31.31%
Inst Owner Change-92.43%
Ins Owners0.45%
Ins Owner Change9.74%
Market Cap39.66M
Analysts72
Price Target37.01 (807.11%)
Short Float %26.25%
Short Ratio0.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.88%
Min EPS beat(2)1.18%
Max EPS beat(2)16.57%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-38.64%
Min Revenue beat(2)-42.36%
Max Revenue beat(2)-34.92%
Revenue beat(4)0
Avg Revenue beat(4)-26.16%
Min Revenue beat(4)-42.36%
Max Revenue beat(4)-6.86%
Revenue beat(8)0
Avg Revenue beat(8)-42.91%
Revenue beat(12)2
Avg Revenue beat(12)-19.38%
Revenue beat(16)2
Avg Revenue beat(16)-139.21%
PT rev (1m)-3.79%
PT rev (3m)1218.28%
EPS NQ rev (1m)-1957.05%
EPS NQ rev (3m)-1805.63%
EPS NY rev (1m)17.98%
EPS NY rev (3m)-1527.6%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)-50.75%
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)-18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.75
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.65
EYN/A
EPS(NY)-8.97
Fwd EYN/A
FCF(TTM)-23.77
FCFYN/A
OCF(TTM)-23.01
OCFYN/A
SpS5.47
BVpS-0.6
TBVpS-2.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.42%
ROA(5y)-60.14%
ROE(3y)-154.55%
ROE(5y)-114.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.08%
Cap/Sales 13.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.51
Quick Ratio 0.33
Altman-Z -15.86
F-Score2
WACC8.52%
ROIC/WACCN/A
Cap/Depr(3y)137.67%
Cap/Depr(5y)200.04%
Cap/Sales(3y)342.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2960.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-839.39%
EPS Next Y35.36%
EPS Next 2Y32.12%
EPS Next 3Y18.57%
EPS Next 5Y14.61%
Revenue 1Y (TTM)143.67%
Revenue growth 3YN/A
Revenue growth 5Y-11.58%
Sales Q2Q%-14.36%
Revenue Next Year74.73%
Revenue Next 2Y143.81%
Revenue Next 3Y95.72%
Revenue Next 5Y64.23%
EBIT growth 1Y5.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.78%
EBIT Next 3Y27.14%
EBIT Next 5Y25.4%
FCF growth 1Y48.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.74%
OCF growth 3YN/A
OCF growth 5YN/A